An efficient method for constructing a recombinant adenovirus (Ad) vector, based on an in vitro ligation, has been developed. To insert the foreign gene into an adenoviral DNA, we introduced three unique restriction sites, I-CeuI, SwaI, and PI-SceI, into the E1 deletion site of the vector plasmid, which contains a complete E1, E3-deleted adenovirus type 5 genome. I-CeuI and PI-SceI are intron-encoded endonucleases with a sequence specificity of at least 9± 10 and 11 bp, respectively. A shuttle plasmid, pHM3, containing multiple cloning sites between the I-CeuI and PI-SceI sites, was constructed. After the gene of interest was inserted into this shuttle plasmid, the plasmid for E1-deleted adenovirus vector could be easily prepared by in vitro ligation using the I-CeuI and PI-SceI sites. SwaI digestion of the ligation products prevented the production of a plasmid containing a parental adenovirus genome (null vector). After transformation into E. coli, more than 90% of the transformants had the correct insert. To make the vector, a PacI-digested, linearized plasmid was transfected into 293 cells, resulting in a homogeneous population of recombinant virus. The large number and strategic location of the unique restriction sites will not only increase the rapidity of production of new firstgeneration vectors for gene transfer but will allow for rapid further improvements in the vector DNA backbone.
INTRODUCTION R
ECOMBINANT ADENOVIRU S VECTORS have been shown to have great promise for gene transfer in basic research as well as for clinical treatment of many diseases (Kozarsky and Wilson, 1993; Kay and Woo, 1994) . They can transduce foreign genes efficiently into both cultured cells and many target organs in vivo. There are more than 40 serotypes of adenovirus (Ad) identified. The Ad type 5 genome has been used most commonly to make recombinant Ad vector. The genome of human Ad is a linear 36-kb, double-stranded DNA genome that encodes more than 50 gene products. In the first-generation Ad vector, the early region 1 (E1) is replaced by the foreign gene and the virus propagated in an E1-trans-complementing cell line such as 293. By deleting E1 and early region 3 (E3) sequences up to about 8 kb of foreign gene can be inserted (Bett et al., 1994) . However, in vitro manipulation of Ad DNA is difficult. Unique and useful restriction sites are limited because of the large size of the genome, making the construction of Ad vectors relatively labor intensive. Two standard methods to make E1-deleted Ad vectors have been developed: an in vitro ligation method (Berkner and Sharp, 1983; Gilardi et al., 1990; Rosenfeld et al., 1991) and a homologous recombination method in 293 cells (Bett et al 1994; Miyake et al., 1996) . The in vitro ligation method uses whole viral DNA genomes and a plasmid containing the left end of the Ad genome with the left inverted terminal repeat (ITR), the packaging signal, and the E1A enhancer sequence (map units 0 to 1.3) . After the gene of interest is inserted downstream of the viral sequence of the plasmid, the fragment containing viral sequence and the gene of interest is excised and ligated into the unique ClaI site (map unit 2.6), replacing a portion of the viral E1 region. Then, the ligated DNA is directly transfected into 293 cells to make recombinant virus. However, this method is rarely used now because the efficiency is low and the recombinant virus requires purification of contaminating wild-type and transgene null viruses related to incomplete restriction digestion and self-religation. One system based on homologous recombination (Bett et al., 1994) uses two plasmids with overlapping fragments that recombine in vivo. The first plasmid contains the entire Ad genome with a deletion of the DNA packaging signal and E1 region. The second plasmid contains the left ITR, packaging signal, and overlapping sequence with the first plasmid. After the gene of interest is introduced into the second plasmid, the two plasmids are cotransfected into 293 cells. The virus, which is produced by the recombination in 293 cells, is isolated through plaque purification. The major limitation to this approach is that the recombination event occurs at a low frequency.
Newer methods for adenoviral preparation are based on homologous recombination of two plasmids, using yeast artificial chromosomes (YACs; Ketner et al., 1994) or bacteria (Chartier et al., 1996; Crouzet et al., 1997; He et al., 1998) . These methods, while more efficient, are more complex. The YAC system requires yeast culture and manipulation (Ketner et al., 1994) , while the Escherichia coli system requires three-step transformations using an additional, nonconventional host bacterial strain (BJ5183recBCsbcBC) (Chartier et al., 1996; Crouzet et al., 1997; He et al., 1998) .
In this article we report the efficient construction of an E1-deleted Ad vector by an improved in vitro ligation method. This system requires a simple in vitro ligation using routine molecular biology reagents and transformation in commonly used bacterial strains.
MATERIALS AND METHODS

Plasmids
Vector plasmids pAdHM1, -2, -3, and -4 were constructed as follows. pHVad2 (provided by HepaVec, Berlin, Germany), which has the left end (bp 1±341 and bp 3524±5790) of the Ad type 5 genome with an E1 deletion, was cut by ClaI and EcoRI, and ligated with oligonucleotides 1 (59 CGTAACTATAACG -GTCCTAAGGTAGCGA G 3 9 ) and 2 (59 AATTCTCGCTAC-CTTAGGACCGTTATAGTT A 39 ) (I-CeuI recognition sequences are underlined), resulting in pAd4. pAd4 was then cut with EcoRI and SalI, and then ligated with oligonucleotides 3 (59 AATTATTTAAATATCTATGTCGGGTGCGGAGAAA -GAGGTAATGAAATGGCA 39 ) and 4 (59 TCGATGC-C AT TT CA TT AC CT CT TT CT CC GC A CC CG AC A TA -GATATTTAAAT 39 ) (PI-SceI and SwaI recognition sequences are underlined and italicized, respectively), resulting in pAd18, which contains I-CeuI, SwaI, and PI-SceI sites. pAd19, which contains the Ad type 5 genome (bp 1 to 21562), was prepared by the insertion of the PacI/BamHI fragment of pTG3602 (Chartier et al., 1996) , which has a full-length Ad type 5 genome flanked with a PacI site, in the plasmid derived from pGEM7Zf(±) (Promega, Madison, WI). The PacI/XcaI fragment of pAd18 and pAd19 were then ligated, resulting in pAd16. The BamHI/PacI fragment (bp 21562 to the right end of the genome) of pTG3602 or pHVad1 (provided by HepaVec), both of which have the Ad type 5 genome with a deletion in the E3 region (bp 28133±30818), were introduced into the ClaI and BamHI sites of pGEM7Zf(±), after the PacI site of pTG3602 and pHVad1 was changed into a ClaI site by using a ClaI linker (New England BioLabs, Beverly, MA), resulting in pAd1 and pAd2, respectively. The fragment of pAd16 digested with PacI and BamHI was then cloned into the NsiI and BamHI sites of pAd1 and pAd2, respectively, after the NsiI site was changed into a PacI site by using a PacI linker (New England BioLabs). The resulting plasmids were named pAdHM1 and pAdHM2, respectively. The ClaI site of pAdHM1 and pAdHM2 was changed into a PacI site by using oligonucleotides 5 (59 CGTTAATTAA 39 ) and 6 (59 CGTTAATTAA 39 ) (PacI recognition sequences are underlined), resulting in pAdHM3 and pAdHM4, respectively. pAdHM1, -2, -3, and -4 have I-CeuI, SwaI, and PI-SceI sites in the E1 deletion region. pAdHM1 and -3 have the Ad genome with a deletion in the E1 region (D E1; bp 342±3523), while pAdHM2 and -4 have the Ad genome with a deletion in the E1 and E3 regions (D E1, bp 342±3523; D E3, bp 28133±30818). pAdHM1 and pAdHM2 have a PacI site at the left end of the Ad genome and a ClaI site at the right end of the genome. pAdHM3 and pAdHM4 have PacI sites at both ends of the Ad genome (Fig. 1A) .
Shuttle plasmid pHM3 was constructed as follows. pUC18 was cut by AatII and HindIII, and ligated with oligonucleotides 7 (59 TAACTATAACGGTCCTAAGGTAGCGA A 39 ) and 8 (59 AGCTTTCGCTACCTTAGGACCGTTATAGT TAACGT 39 ) (I-CeuI recognition sequences are underlined), resulting in pHM1. pHM1 was cut with EcoRI and PvuII, and then ligated with oligonucleotides 9 (59 AATTCTGGCAAACAGCTAT -TATGGGTATTATGGGT 39 ) and 10 (59 ACCCATAATACC -CATAATAGCTGTTTGCCA G 39 ) (PI-PspI recognition sequences are underlined), resulting in pHM2. This plasmid has another intron-coded enzyme (PI-PspI) recognition site. The PI-PspI fragment of pHM2 was then ligated with oligonucleotides 11 (59 ATCTATGTCGGGTGCGGAGAAAGAG -GTAATGAAATGGCATTAT 39 ) and 12 (59 TGCCATTT-CATTACCTCTTTCTCCGCACCCGACATA GATATAA 39 ) (PI-SceI recognition sequences are underlined). The resulting plasmid was named pHM3 (Fig. 1B) . pHM3 contains the pUC18-derived multicloning site between the I-CeuI and PI-SceI sites. All mutations were sequenced with a Sequenase version 2.0 DNA sequencing kit (New England Nuclear, Boston, MA).
Construction of recombinant Ad vector DNA containing human a 1 -antitrypsin expression cassette
The XhoI fragment of pBSRSVhAAT (Kay et al., 1992) , containing the Rous sarcoma virus long terminal repeat (RSV LTR) promoter, human a 1 -antitrypsin (hAAT) cDNA, and bovine growth hormone polyadenylation signal, was cloned into the SalI site of pHM3. Depending on the orientation of the hAAT expression cassette, the resulting plasmids were named pHM3-hAAT1 and pHM3-hAAT2 (Fig. 1C) . The strategy for construction of E1-and E3-deleted adenovirus vector. The expression cassette of interest (RSVhAATbPA) was inserted into the SalI site of the multicloning site of pHM3, and the resulting plasmid, pHM3-hAAT1, was digested with I-CeuI and PI-SceI. The fragment containing the hAAT expression cassette was ligated with pAdHM4 digested with I-CeuI and PI-SceI. Transformation into DH5a was performed after the ligation samples were digested with SwaI to reduce the formation of colonies containing parental vector plasmid (pAdHM4).
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was isolated by gel extraction after agarose gel electrophoresis. pAdHM4 was also digested with I-CeuI and PISceI, but the digested DNA was purified by phenol±chloroform extraction and ethanol precipitation. Digested pAdHM4 (0.1 m g) was then ligated to the pHM3 fragment containing the hAAT expression cassette at 16°C for more than 2 hr. To reduce the background with the parental plasmid, pAdHM4, the ligation products were treated at 65°C for 20 min to inactivate T4 DNA ligase, and then digested with SwaI. SwaI cuts the parental plasmid (pAdHM4), but not the recombinant plasmid. Finally, the DNAs were transformed with electrocompetent DH5a (chemical-competent DH5a can be also used), and the individual clones were screened by restriction analysis (Fig.  1C) . Large-scale preparation of plasmid pAdHM4-hAAT was performed by using a Qiagen Plasmid Maxi-kit (Qiagen, Chatsworth, CA). No rearrangement of the plasmid during amplification was observed.
Generation of adenovirus vector
pAdHM4-hAAT was linearized by the digestion with PacI and purified by phenol±chloroform extraction and ethanol precipitation. The DNA was transfected into subconfluent 293 cells plated in a 60-mm dish with SuperFect (Qiagen) according to the manufacturer's instructions. The cells were cultured with Dulbecco's modified Eagle' s medium (DMEM) (GIBCO, Grand Island, NY) containing 10% fetal calf serum (FCS) or with 0.5% overlaid agarose±DMEM containing 10% FCS. Ten days later, the cells were harvested and five independent plaques were isolated. The virus was released by four cycles of freezing and thawing, and amplified in 293 cells. Recombinant virus expressing hAAT was referred to as AdhAAT. The titer of the virus was measured by standard plaque assay in 293 cells (Kay et al., 1995) .
To analyze the viral DNA, Ad DNA was isolated from the cells with full cytopathic effect (CPE) as described previously (Lieber et al., 1996) . Briefly, 293 cells with full CPE were digested with 0.1% pronase in 10 mM Tris-HCl (pH 7.5)±1% sodium dodecyl sulfate±10 mM EDTA overnight at 37°C. After phenol±chloroform extraction, DNA was ethanol precipitated, dissolved in TE (10 mM Tris [pH 7.5], 1 mM EDTA), and digested with HindIII or I-CeuI/PI-SceI, and analyzed in a 0.8% agarose gel stained with ethidium bromide.
hAAT expression in HeLa cells infected with AdhAAT
HeLa cells (8 3 10 5 cells) were seeded into a 60-mm dish, and the next day they were treated with AdhAAT (at a multiplicity of infection [MOI] of 20 or 100). The cells were cultured with DMEM containing 10% FCS and 2 days later hAAT concentrations in the medium were determined by enzymelinked immunosorbent assay as previously described (Kay et al., 1995) .
RESULTS
Construction and characterization of E1-deleted adenovirus vector DNA
To construct the plasmid with recombinant Ad vector DNA containing a foreign gene at the E1 deletion site by a single in vitro ligation, three unique restriction sites (I-CeuI, SwaI, and PISceI) were introduced into the E1 deletion site of the vector plasmid containing a complete vector genome. I-CeuI (Marshall and Lemieux, 1991) and PI-SceI (Gimble and Thorner, 1992) are intron-encoded endonucleases that recognize at least 9±10 and 11 bp, respectively. SwaI is a rare-cutting restriction enzyme with a sequence specificity of 8 bp. The I-CeuI and PI-SceI sites were used for the insertion of foreign gene, while the SwaI site was used to reduce the generation of parental, nonrecombined plasmid. The resulting vector plasmids, pAdHM1, -2, -3, and -4, contain the complete Ad genome minus the E1 (pAdHM1, -3) or E1/E3 region (pAdHM2, -4), have PacI (pAdHM3, -4) or PacI/ClaI (pAdHM1, -2) sites at both ends of the Ad genome, and have I-CeuI, SwaI, and PI-SceI sites in the E1 deletion site (Fig. 1A) . HindIII and PacI treatment of pAdHM4 produced the expected fragments shown in Fig. 2 (lanes 2 and 3) .
A shuttle plasmid, pHM3, containing a pUC18-derived multicloning site between the I-CeuI and PI-SceI sites was constructed (Fig. 1B) product was called pHM3-hAAT1. The corresponding Ad vector DNA, pAdHM4-hAAT (Fig. 1C) , was produced by in vitro ligation of I-CeuI/PI-SceI-digested pAdHM4 and pHM3-hAAT1 (Fig. 1C) . I-CeuI and PI-SceI digestion of pAdHM4-hAAT produced the expected 2.1-kb DNA fragment corresponding to an hAAT expression cassette in addition to the expected adenoviral fragments (Fig. 2, lane 4) . The expected DNA fragments were also detected with either PacI or PacI/HindIII digestion (Fig. 2, lanes 5 and 6) . More than 90% (15 of 16 clones) of the transformants had the correct restriction pattern.
Generation of adenovirus vector expressing hAAT
To demonstrate that pAdHM4-hAAT was able to produce Ad vector in 293 cells, PacI-linearized pAdHM4-hAAT DNA was transfected into 293 cells and the cells were cultured for 10 days. The cell lysates were used to infect fresh 293 cells, followed by routine adenovirus preparation. The correctness of the viral DNA was verified by double digestion with I-CeuI and PI-SceI (Fig. 2, lane 7) or HindIII digestion (Fig. 2, lane 8) and found to have the same pattern as PacI/HindIII-digested pAdHM4-hAAT plasmid DNA. For further confirmation, 17 independent plaques were found to have identical DNA restriction patterns (results for 5 clones are shown in Fig. 2, lanes  9±13) . Virus was not produced by the transfection of circular plasmid (pAdHM4-hAAT) into 293 cells, consistent with previous reports (Chartier et al., 1996; He et al., 1998) . Finally, to confirm the functionality of the vector, robust hAAT expression was detected in AdhAAT-infected HeLa cells (Table 1) .
DISCUSSION
We have developed a simple and efficient method for constructing recombinant E1-deleted adenoviral vectors by in vitro ligation. Previously, it has been difficult to manipulate Ad DNA in vitro because of the paucity of unique useful restriction sites. Thus, by insertion of unique I-CeuI, SwaI, and PI-SceI sites in the E1-deleted region of the plasmid with an E1-deleted Ad genome, we could easily produce a vector by a simple in vitro ligation. The shuttle plasmid pHM3, which has multicloning sites between the I-CeuI and PI-SceI sites, allowed for the gene of interest to be easily introduced into the E1 deletion region is probably as efficient in terms of recombinant viral production as the method described here; however, the E. coli system requires a three-step transformation, including the use of two different E. coli strains. This system does allow easy insertion of foreign genes into the E3 region as well as the E1 region. A cosmid Ad vector plasmid cloning strategy requires an additional l packaging step (Fu and Deisseroth, 1997). A flow chart comparing the properties of the different homologous recombination systems is shown in Fig. 3 .
The major advantage of our system is its simplicity; it requires only a routine two-step transformation protocol that is familiar to any molecular biologist. Because of the paucity of generation of wild-type or null vectors, the time-consuming plaque purification procedure is not absolutely required to produce virus. Furthermore, the system will allow for the easy modification of vector DNA backbone, or for addition of various expression cassettes, by routine cloning because of the many unique restriction sites in pAdHM1 and pAdHM2. These include PacI (left end of the genome); I-CeuI, SwaI, and PI-SceI; XcaI (bp 5764, in the case of pAdHM2); PmeI (bp 13255); BamHI (bp 21562); SpeI (bp27082); SrfI (bp 27527); and ClaI (right end of the genome). In addition, this system may allow for the production of vectors that have proven difficult to make because they produce a protein that interferes with DNA recombination, or because they reduce cell viability because of their prolonged expression in mammalian cells. In general, the use of this system should facilitate the construction of additional Ad vectors for gene transfer in basic research as well as gene therapy.
